131 related articles for article (PubMed ID: 15105775)
1. [Therapeutic behaviour for a HCV+ patient].
Buffet C
Presse Med; 2004 Apr; 33(7):497-8. PubMed ID: 15105775
[No Abstract] [Full Text] [Related]
2. [New triple therapy in chronic hepatitis C. Increased patient chances].
Stiefelhagen P
MMW Fortschr Med; 2011 Sep; 153(39):20. PubMed ID: 21991830
[No Abstract] [Full Text] [Related]
3. [Clinical significance of measuring HCV-RNA levels in patients with chronic hepatitis C by IFN treatment, including combination therapy with ribavirin].
Kakumu S
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):507-10. PubMed ID: 15359851
[No Abstract] [Full Text] [Related]
4. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
[TBL] [Abstract][Full Text] [Related]
5. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.
Berenguer M; Prieto M; Palau A; Carrasco D; Rayón JM; Calvo F; Berenguer J
Eur J Gastroenterol Hepatol; 2004 Nov; 16(11):1207-12. PubMed ID: 15489583
[TBL] [Abstract][Full Text] [Related]
6. [Combination therapy of interferon plus ribavirin for chronic hepatitis C].
Asahina Y; Izumi N
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):467-73. PubMed ID: 15359843
[No Abstract] [Full Text] [Related]
7. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
McHutchison JG; Manns M; Patel K; Poynard T; Lindsay KL; Trepo C; Dienstag J; Lee WM; Mak C; Garaud JJ; Albrecht JK;
Gastroenterology; 2002 Oct; 123(4):1061-9. PubMed ID: 12360468
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of response to treatment in chronic hepatitis C].
Leroy V; Hilleret MN
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B23-31. PubMed ID: 12180294
[No Abstract] [Full Text] [Related]
9. Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection.
Flemming JA; Terrault NA
Infect Dis Clin North Am; 2012 Dec; 26(4):903-15. PubMed ID: 23083823
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C].
Iyoda K; Kato M
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):502-5. PubMed ID: 15359850
[No Abstract] [Full Text] [Related]
11. Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt.
Kanda T; Matsuoka S; Moriyama M
Hepatol Int; 2018 Jul; 12(4):291-293. PubMed ID: 29992512
[No Abstract] [Full Text] [Related]
12. [Quality of life of patients with chronic hepatitis C: effect of treatments].
Couzigou P
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B257-63. PubMed ID: 12180299
[No Abstract] [Full Text] [Related]
13. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
14. [Type 2 diabetes mellitus with histological finding of nonalcoholic steatohepatitis following combination therapy with interferon and ribavirin for chronic hepatitis C].
Yagi N; Uchikoga O; Nishumi T; Shibutani Y; Fukunaga K; Yagi N; Morita M; Tani S; Murao S
Nihon Shokakibyo Gakkai Zasshi; 2005 Aug; 102(8):1045-50. PubMed ID: 16124712
[No Abstract] [Full Text] [Related]
15. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
Ohya K; Akuta N; Suzuki F; Fujiyama S; Kawamura Y; Kominami Y; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2018 May; 90(5):919-925. PubMed ID: 29315652
[TBL] [Abstract][Full Text] [Related]
16. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
Shoeb D; Dearden J; Weatherall A; Bargery C; Moreea S; Alam S; White E; Vila X; Freshwater D; Ryder S; Mills PR; Alexander GJ; Forton D; Foster GR
J Hepatol; 2014 Apr; 60(4):699-705. PubMed ID: 24291239
[TBL] [Abstract][Full Text] [Related]
17. Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report.
Igawa T; Fushimi S; Matsuo R; Ikeda F; Nouso K; Yoshino T; Nakatsukasa H
Clin J Gastroenterol; 2014 Oct; 7(5):465-70. PubMed ID: 26184030
[TBL] [Abstract][Full Text] [Related]
18. [Peripheral facial paralysis during interferon treatment in hepatitis C: recovery without antiviral therapy withdrawal].
de Artaza T; Sánchez JJ; González C; Pérez-Grueso MJ; Repiso A; Gómez R; Potenciano JL
Gastroenterol Hepatol; 2004; 27(7):434-5. PubMed ID: 15461949
[No Abstract] [Full Text] [Related]
19. [Treatment of patients with chronic hepatitis C who never had been treated].
Hézode C
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B38-49. PubMed ID: 12180307
[No Abstract] [Full Text] [Related]
20. [Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration].
Fukuda A
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):493-6. PubMed ID: 15359848
[No Abstract] [Full Text] [Related]
[Next] [New Search]
